| Ytd | -32.10% | |
| 1y | -48.60% |
| Open | 1.12 | Prev Close | 1.13 | Low | 1.10 | High | 1.14 | Mkt Cap | 41.55M |
| Vol | 124.38K | Avg Vol | 162.38K | EPS | -2.49 | P/E | N/A | Forward P/E | -1.38 |
| Beta | 0.67 | Short Ratio | 0.60 | Inst. Own | 34.68% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 1.21 | 200-d Avg | 1.41 | 1yr Est | 18.40 |
MGX News
EMERYVILLE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be lim
MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Prepared Remarks Transcript
Wells Fargo analyst Yanan Zhu maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Overweight an
Metagenomi Therapeutics (MGX) came out with a quarterly loss of $0.73 per share versus the Zacks Con
Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.73) per share which missed the analyst cons
MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Transcript
EMERYVILLE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Prolynx, a biotechnology company developing a
Chardan Capital analyst Keay Nakae maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Buy and
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswir
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be lim
EMERYVILLE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (th
Wells Fargo analyst Yanan Zhu maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Overweight an
Metagenomi Therapeutics (MGX) came out with a quarterly loss of $0.61 per share versus the Zacks Con
Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.61) per share which missed the analyst cons
On track for regulatory submission of MGX-001 to advance global clinical program, including investig
Metagenomi, Inc. (NASDAQ: MGX - Get Free Report) has earned a consensus recommendation of "Moderate
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing compan
Metagenomi Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary C
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be lim
Metagenomi (NASDAQ: MGX - Get Free Report) is expected to be issuing its Q4 2025 results before the
Shares of Metagenomi, Inc. (NASDAQ: MGX - Get Free Report) have been given a consensus rating of "Mo
Metagenomi Therapeutics (MGX) came out with a quarterly loss of $0.6 per share versus the Zacks Cons
Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity i
Metagenomi Therapeutics, Inc. (MGX) Presents at TD Cowen 46th Annual Health Care Conference Transcri
EMERYVILLE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (t
New name reflects the Company's strategic evolution focused on later-stage preclinical assets le
Metagenomi reports curative-level FVIII activity for MGX-001 in primates and plans IND filing in 202
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a str
